OTCMKTS:ERBA

ERBA Diagnostics Competitors

$0.04
0.00 (0.00 %)
(As of 08/27/2020)
Add
Compare
Today's Range
$0.04
$0.04
50-Day Range
$0.04
$0.04
52-Week Range
$0.01
$0.31
VolumeN/A
Average Volume12,697 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta0.76

Competitors

ERBA Diagnostics (OTCMKTS:ERBA) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying ERBA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ERBA Diagnostics, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

Acusphere (OTCMKTS:ACUS) and ERBA Diagnostics (OTCMKTS:ERBA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Acusphere and ERBA Diagnostics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
ERBA Diagnostics0000N/A

Volatility & Risk

Acusphere has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500. Comparatively, ERBA Diagnostics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Profitability

This table compares Acusphere and ERBA Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
ERBA DiagnosticsN/AN/AN/A

Valuation and Earnings

This table compares Acusphere and ERBA Diagnostics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
ERBA DiagnosticsN/AN/AN/AN/AN/A

Summary

ERBA Diagnostics beats Acusphere on 1 of the 1 factors compared between the two stocks.

ERBA Diagnostics (OTCMKTS:ERBA) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares ERBA Diagnostics and Affymax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ERBA DiagnosticsN/AN/AN/A
AffymaxN/AN/AN/A

Earnings & Valuation

This table compares ERBA Diagnostics and Affymax's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ERBA DiagnosticsN/AN/AN/AN/AN/A
AffymaxN/AN/AN/AN/AN/A

Volatility and Risk

ERBA Diagnostics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Affymax has a beta of 2.77, suggesting that its stock price is 177% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for ERBA Diagnostics and Affymax, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ERBA Diagnostics0000N/A
Affymax0000N/A

Summary

Affymax beats ERBA Diagnostics on 1 of the 1 factors compared between the two stocks.

ERBA Diagnostics (OTCMKTS:ERBA) and ARYx Therapeutics (OTCMKTS:ARYX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares ERBA Diagnostics and ARYx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ERBA DiagnosticsN/AN/AN/A
ARYx TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares ERBA Diagnostics and ARYx Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ERBA DiagnosticsN/AN/AN/AN/AN/A
ARYx TherapeuticsN/AN/AN/AN/AN/A

Risk & Volatility

ERBA Diagnostics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, ARYx Therapeutics has a beta of -0.53, suggesting that its stock price is 153% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for ERBA Diagnostics and ARYx Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ERBA Diagnostics0000N/A
ARYx Therapeutics0000N/A

Summary

ERBA Diagnostics beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

AtheroNova (OTCMKTS:AHROQ) and ERBA Diagnostics (OTCMKTS:ERBA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Analyst Ratings

This is a summary of current ratings and target prices for AtheroNova and ERBA Diagnostics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AtheroNova0000N/A
ERBA Diagnostics0000N/A

Profitability

This table compares AtheroNova and ERBA Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtheroNovaN/AN/AN/A
ERBA DiagnosticsN/AN/AN/A

Volatility & Risk

AtheroNova has a beta of -8.71, suggesting that its share price is 971% less volatile than the S&P 500. Comparatively, ERBA Diagnostics has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Valuation & Earnings

This table compares AtheroNova and ERBA Diagnostics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtheroNovaN/AN/AN/AN/AN/A
ERBA DiagnosticsN/AN/AN/AN/AN/A

Summary

ERBA Diagnostics beats AtheroNova on 1 of the 1 factors compared between the two stocks.

ERBA Diagnostics (OTCMKTS:ERBA) and China Botanic Pharmaceutical (OTCMKTS:CBPI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Valuation and Earnings

This table compares ERBA Diagnostics and China Botanic Pharmaceutical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ERBA DiagnosticsN/AN/AN/AN/AN/A
China Botanic PharmaceuticalN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for ERBA Diagnostics and China Botanic Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ERBA Diagnostics0000N/A
China Botanic Pharmaceutical0000N/A

Profitability

This table compares ERBA Diagnostics and China Botanic Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ERBA DiagnosticsN/AN/AN/A
China Botanic PharmaceuticalN/AN/AN/A

Risk and Volatility

ERBA Diagnostics has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, China Botanic Pharmaceutical has a beta of 17.09, suggesting that its share price is 1,609% more volatile than the S&P 500.

Summary

China Botanic Pharmaceutical beats ERBA Diagnostics on 1 of the 1 factors compared between the two stocks.

China Dongsheng International (OTCMKTS:CDSG) and ERBA Diagnostics (OTCMKTS:ERBA) are both consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for China Dongsheng International and ERBA Diagnostics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Dongsheng International0000N/A
ERBA Diagnostics0000N/A

Valuation & Earnings

This table compares China Dongsheng International and ERBA Diagnostics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Dongsheng InternationalN/AN/AN/AN/AN/A
ERBA DiagnosticsN/AN/AN/AN/AN/A

Profitability

This table compares China Dongsheng International and ERBA Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Dongsheng InternationalN/AN/AN/A
ERBA DiagnosticsN/AN/AN/A

Risk and Volatility

China Dongsheng International has a beta of 13.38, suggesting that its stock price is 1,238% more volatile than the S&P 500. Comparatively, ERBA Diagnostics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Summary

China Dongsheng International beats ERBA Diagnostics on 1 of the 1 factors compared between the two stocks.


ERBA Diagnostics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.07flat$0.00N/A0.00Gap Up
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.02flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07flat$0.00N/A0.00Gap Down
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.06flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20
DDXSQ
Diadexus
0.0$0.00flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$31.24flat$0.00N/A0.00
HRBR
Harbor Diversified
0.0$1.84flat$0.00$263.61 million0.00High Trading Volume
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00Gap Up
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00Gap Up
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Up
PARD
Poniard Pharmaceuticals
0.5$0.05flat$0.00N/A0.00Gap Down
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.06flat$0.00$26.09 million0.00Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00Gap Up
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.